Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation ASCT in Participants with Newly Diagnosed Multiple Myeloma NDMM
A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated with P-BCMA-101
A Phase I, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma Pro00039777
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone Dara-VCD Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Study Type: Treatment
Phase: III
NCTID: NCT06022939
Principal Investigator:
Muhammad Umair Mushtaq
Expanded Access Protocol EaP For Subjects Receiving Idecabtagene vicleucel That Is Nonconforming For commercial Release
Study Type: Treatment
Phase: N/A
NCTID: NCT04771078
Principal Investigator:
Nausheen Ahmed
A Phase II, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma
Phase I, Open Label, Study of B-cell Maturation Antigen BCMA-directed CAR-T cells in Adult Patients with Multiple Myeloma
MonumentTAL-3: 64407564MMY3002: A Phase III Randomized Study Comparing Talquetamab SC in Combination with Daratumumab SC and Pomalidomide Tal-DP or Talquetamab SC in Combination with Daratumumab SC Tal-D versus Daratumumab SC, Pomalidomide and Dexamethasone DPd, in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia AML: A MyeloMATCH Treatment Trial
Study Type: Treatment
Phase: II
NCTID: NCT06317649
Principal Investigator:
Jesus Gonzalez Lugo